Story perspectives

Takeda's Zasocitinib Shows Promising Results for Clear Skin

4/2/2026

Summary

Story summary

About 70% of participants achieved clear or nearly clear skin within 16 weeks, and Zasocitinib significantly outperformed apremilast.
Takeda Pharmaceuticals conducted the trials, enrolling nearly 1,800 adults across 21 countries.
More than 90% of patients maintained clear skin after nine months, indicating rapid and lasting effects.
Takeda plans to submit Zasocitinib for FDA approval within the year.
No serious safety concerns were reported, and mild side effects were common.

1 of 1

Story summary

About 70% of participants achieved clear or nearly clear skin within 16 weeks, and Zasocitinib significantly outperformed apremilast.
Takeda Pharmaceuticals conducted the trials, enrolling nearly 1,800 adults across 21 countries.
More than 90% of patients maintained clear skin after nine months, indicating rapid and lasting effects.
Takeda plans to submit Zasocitinib for FDA approval within the year.
No serious safety concerns were reported, and mild side effects were common.